Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > Articles online first > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2019 Dec 09



To subscribe PROMO
Submit an article
Recommend to your librarian


Publication history
Cite this article as



The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2019 Dec 09

DOI: 10.23736/S1824-4785.19.03173-X


language: English

82Rubidium chloride PET discrimination of recurrent intracranial malignancy from radiation necrosis

Ephraim E. PARENT 1, Ila SETHI 2 , Jonathon NYE 2, Chad HOLDER 2, Jeffrey J. OLSON 3, Jeffrey SWITCHENKO 4, Funmilayo TADE 5, Oladunni O. AKIN-AKINTAYO 2, Olayinka A. ABIODUN-OJO 2, Akinyemi AKINTAYO 2, David M. SCHUSTER 2

1 Department of Radiology, Mayo Clinic, Jacksonville, FL, USA; 2 Department of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, GA, USA; 3 Department of Neurosurgery, Emory University School of Medicine, Atlanta, GA, USA; 4 Bioinformatics and Biostatistics Shared Resource, Winship Cancer Institute of Emory, University, Atlanta, GA, USA; 5 Department of Radiology, Loyola University, Chicago, IL, USA


BACKGROUND: Accurate identification and discrimination of post treatment changes from recurrent disease remains a challenge for patients with intracranial malignancies despite advances in molecular and magnetic resonance imaging. We have explored the ability of readily available Rubidium-82 chloride (82RbCl) PET to identify and distinguish progressive intracranial disease from radiation necrosis in patients previously treated with radiation therapy.
METHODS: Six patients with a total of 9 lesions of either primary (n=3) or metastatic (n=6) intracranial malignancies previously treated with stereotactic radiation surgery (SRS) and persistent contrast enhancement on MRI underwent brain 82RbCl PET imaging. Two patients with arteriovenous malformations previously treated with SRS, also had brain 82RbCl PET imaging for a total of 11 lesions studied. Histological confirmation via stereotactic biopsy/excisional resection was obtained for 9 lesions with the remaining 2 classified as either recurrent tumor or radiation necrosis based on subsequent MRI examinations. 82RbCl PET time activity curve analysis was performed which comprised lesion SUVmax, contralateral normal brain SUVmax, and tumor to background ratios (TBmax).
RESULTS: 82RbCl demonstrates uptake greater than normal brain parenchyma in all lesions studied. Time activity curves demonstrated progressive uptake of 82RbCl in all lesions without evidence of washout. While recurrent disease demonstrated a greater mean SUVmax compared to radiation necrosis, no statistically significant difference between lesion SUVmax nor TBmax was found (p>0.05).
CONCLUSIONS: 82RbCl PET produces high-contrast uptake of both recurrent disease and radiation necrosis compared to normal brain. However, no statistically significant difference was found between recurrent tumor and radiation necrosis.

KEY WORDS: 82RbCl; Glioma; Intracranial metastasis; PET

top of page